The construction projects, which have already begun, will be finalised gradually from the end of 2027 through 202
The facility is expected to become operational by FY2028-29
Nadda underlined that India’s policy framework is aligned with this transformation
Investment marks continued progress against AbbVie's $100 billion commitment to U.S. R&D and capital investments, including manufacturing, over the next decade
The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers
The project entails a total planned capital expenditure of approximately Rs. 500 - 520 crore
Net sales reached CHF 1,327.8 million, up 2.6% year-on-year in Swiss francs, or 4.3% at constant exchange rates
Expansion at the Oss (NL) site adds capacity and R&D capabilities, supporting the development and manufacturing of ADCs and other novel bioconjugates from First-in-Human to commercialization
Subscribe To Our Newsletter & Stay Updated